The National Security Commission on Emerging Biotechnology (NSCEB) was established by Congress in 2022 as part of the National Defense Act. The NSCEB was tasked with conducting a thorough review of how advancements in emerging biotechnology and related technologies will shape current and future activities of the Department of Defense. This fireside chat between Michelle […]
As the former director of the Center for Biologics Evaluation and Research at the FDA, Peter Marks, MD, PhD, discusses new drug and biologic developments that also gave him insight into what is coming in the future. […]
Halia Therapeutics CEO David Bearss, PhD, Mark Ott, MD, dean of the BYU School of Medicine, and Bob Carter, MD, PhD, CEO of University of Utah Health, discussed how the healthcare system will deal with the upcoming “silver tsunami.” […]
Michelle Holyoak and Jacey Skinner discussed several topics affecting the life sciences industry, including FTC policy around non-compete agreements, regulating pharmacy benefit managers, regulation of mergers and acquisitions, and other policies affecting the industry. […]
Dr. Michelle Tarver, Director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration, joined the 2025 Mayer Brown Utah Life Sciences Summit via live video feed and host a town hall meeting. Dr. Tarver provided opening remarks then entertains questions from the audience. This presentation was recorded on November […]
Carter Dredge, PhD, Bus.D, executive director, Intermountain Health Institute and a Cambridge Fellow gave an insightful presentation about how AI is transforming healthcare by driving novel innovation in care delivery models that reduces costs, expands access and personalizes treament – making the impossible, possible. This presentation was given on November 12, 2025 at the 2025 […]